Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Regeneron Wins Expanded Eylea Approval for CRVO

Washington Drug Letter

Oct. 1, 2012 | Vol. 44 No. 39

Regeneron Wins Expanded Eylea Approval for CRVO

The FDA approved a second indication for Regeneron Pharmaceuticals’ Eylea to treat macular edema following central retinal vein occlusion (CRVO).

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Orphan Drugmaker Raptor Wins FDA Approval for Lead Product Procysbi FDA Approves OTC Plan B Drug But Not in Response to Court Order Orphan Drugmaker Raptor Wins FDA Approval for Lead Product Procysbi FDA Advisers Fret Aveed; Support GSK’s COPD Drug

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.